Antidepressant combinations: Widely used, but far from empirically validated

Canadian Journal of Psychiatry

Volumn 56, Issue 6, 2011, Pages 317-323

  Thase, Michael E ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Antidepressants; Combined therapy; Polypharmacy; Treatment resistant depression

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; LITHIUM; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; HUMAN; MAJOR DEPRESSION; MONOTHERAPY; NEUROTRANSMISSION; PSYCHOPHARMACOLOGY; REMISSION; REVIEW;

EID: 79960458333     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371105600602     Document Type: Review

References (15)

1. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York (NY): Raven Press, Ltd; 1995. p 1081-1097.
2. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995;12:185-219.
3. Davidson J, McLeod M, Law-Yone B, et al. A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. Arch Gen Psychiatry. 1978;35:639-642. (Pubitemid 8333777)
4. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology. 1986;90:131-138.
5. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord. 1990;18:289-299.
6. Anderson IM. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety. 1998;7:11-17.
7. Lam RW, Wan DDC, Cohen NL, et al. Combining antidepressants for treatment-resistant depression: a review. J Clin Psychiatry. 2002;63:685-693.
8. Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry. 1994;151:1372-1374. (Pubitemid 24281764)
9. Nelson JC, Mazure CM, Bowers MB, et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1991;48:303-307.
10. Fava M, Alpert J, Nierenberg A, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol. 2002;22:379-387. (Pubitemid 34810327)
11. Nelson JC, Mazure CM, Jatlow PI, et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry. 2004;55:296-300. (Pubitemid 38117167)
12. Lam RW, Hossie H, Solomons K, et al. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J Clin Psychiatry. 2004;65:337-340.
13. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243-1252.
14. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354:1231-1242.
15. Landen M, Bjorling G, Agren H, et al. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry. 1998;59:664-668. (Pubitemid 29068311)